In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Signalife receives $102m lifeline:

This article was originally published in Clinica

Executive Summary

Biomedical signal monitoring specialist Signalife has received a welcome financial boost in the shape of a $102m funding from YA Global Investments. The Greenville, South Carolina-based company was issued with an AMEX deficiency letter in June, stating that the company's shareholder equity price had fallen below the minimum threshold for companies with market caps of less than $50m. Signalife has received $2m upfront from the sale of common stock and warrants to YA, and has entered a standby equity distribution agreement with the investment firm that will see the sale of $100m in additional stock over the next three years. As well as repairing the company's stock market position, the funding will also help sales and marketing of its lead product, the Fidelity 100 heart monitor, designed to detect early signs of cardiovascular disease.

You may also be interested in...

Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.

venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept

Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.

FDA Wants To Put Hep C Tests On 510(k) Pathway

The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts